{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T04:43:39Z","timestamp":1788583419682,"version":"build-2803163510"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,3]]},"abstract":"<jats:p>Using data from a pilot study conducted in North-Western Romania, we aimed to estimate the prevalence of abnormal cytology and positive high-risk human papillomavirus (hr-HPV) test results in an ethnically diverse screening population and to assess the agreement between cytology and hr-HPV testing to evaluate the feasibility of integrating the latter as a primary test in the national cervical cancer screening program. The cross-sectional pilot study included Roma women, other ethnic minorities, and women in rural remote areas. Samples were taken for liquid-based cytology and hr-HPV testing (Hybrid Capture 2 DNA test) by a mobile health unit. The prevalence of positive screening results and the agreement between cytology and hr-HPV testing were estimated by <jats:italic toggle=\"yes\">\u03ba<\/jats:italic> coefficient. A total of 1019 women were included in the study. The population prevalence of positive screening results was similar for both tests (12%). The prevalence of abnormal cytology increased with increasing age, whereas the prevalence of positive hr-HPV test showed a bimodal age pattern. Substantial differences in the prevalence of abnormal cytology were found by ethnicity, with highest prevalence in Romanian women (14%), followed by Roma women (6%) and women of other ethnicities (5%) (<jats:italic toggle=\"yes\">P\u2009<\/jats:italic>=<jats:italic toggle=\"yes\">\u2009<\/jats:italic>0.002). Similar ethnic differences in the prevalence of positive hr-HPV test were not observed. The overall agreement of positive screening results between the two methods was fair (<jats:italic toggle=\"yes\">\u03ba\u2009<\/jats:italic>=<jats:italic toggle=\"yes\">\u2009<\/jats:italic>0.25; 95% confidence interval<jats:italic toggle=\"yes\">\u2009<\/jats:italic>=<jats:italic toggle=\"yes\">\u2009<\/jats:italic>0.18\u20130.30, <jats:italic toggle=\"yes\">P\u2009<\/jats:italic>&lt;<jats:italic toggle=\"yes\">\u2009<\/jats:italic>0.001) and ranged from poor to substantial depending on the age group. The prevalence of abnormal cytology result was high and similar to the prevalence of positive hr-HPV test result, which could allow for the implementation of hr-HPV testing as a primary test in the cervical cancer screening program in Romania.<\/jats:p>","DOI":"10.1097\/cej.0000000000000522","type":"journal-article","created":{"date-parts":[[2019,4,29]],"date-time":"2019-04-29T07:48:25Z","timestamp":1556524105000},"page":"141-148","source":"Crossref","is-referenced-by-count":8,"title":["Prevalence of positive screening test results and agreement between cytology and human papillomavirus testing in primary cervical cancer screening in North-Western Romania"],"prefix":"10.1097","volume":"29","author":[{"given":"Ofelia","family":"\u015euteu","sequence":"first","affiliation":[{"name":"Prevention and Cancer Control"},{"name":"Epidemiology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihaiela L.","family":"Blaga","sequence":"additional","affiliation":[{"name":"Prevention and Cancer Control"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari","family":"Nyg\u00e5rd","sequence":"additional","affiliation":[{"name":"Department of Research, Cancer Registry of Norway, Institute of Population-Based Cancer Research"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarit K.","family":"Leinonen","sequence":"additional","affiliation":[{"name":"Department of Research, Cancer Registry of Norway, Institute of Population-Based Cancer Research"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Nicula","sequence":"additional","affiliation":[{"name":"Prevention and Cancer Control"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodica","family":"P\u0103i\u015f","sequence":"additional","affiliation":[{"name":"Anatomopathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Coza","sequence":"additional","affiliation":[{"name":"Prevention and Cancer Control"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patriciu A.","family":"Cadariu","sequence":"additional","affiliation":[{"name":"Surgical Oncology, Institute of Oncology \u2018Prof. Dr. Ion Chiricu\u0163\u0103\u2019"},{"name":"Surgical Oncology, \u2018Iuliu Ha\u0163ieganu\u2019 University of Medicine and Pharmacy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Melnic","sequence":"additional","affiliation":[{"name":"Romanian Cancer Society, Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trude","family":"Andreassen","sequence":"additional","affiliation":[{"name":"Department of Research, Cancer Registry of Norway, Institute of Population-Based Cancer Research"},{"name":"Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Hashim","sequence":"additional","affiliation":[{"name":"Department of Research, Cancer Registry of Norway, Institute of Population-Based Cancer Research"},{"name":"Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway"},{"name":"Department of Community Medicine, Faculty of Health Sciences, University of Troms\u00f8, The Arctic University of Norway, Troms\u00f8, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabete","family":"Weiderpass","sequence":"additional","affiliation":[{"name":"Department of Research, Cancer Registry of Norway, Institute of Population-Based Cancer Research"},{"name":"Department of Community Medicine, Faculty of Health Sciences, University of Troms\u00f8, The Arctic University of Norway, Troms\u00f8, Norway"},{"name":"Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden"},{"name":"Genetic Epidemiology Group, Folkh\u00e4lsan Research Center and Faculty of Medicine, University of Helsinki, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230902","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1097\/CEJ.0b013e32832abd5e","article-title":"Prevalence and distribution of high-risk human papillomavirus in Greece.","volume":"18","author":"Agorastos","year":"2009)","journal-title":"Eur J Cancer Prev"},{"key":"R2-20230902","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.socscimed.2017.04.040","article-title":"Controversies about cervical cancer screening: a qualitative study of Roma women\u2019s (non)participation in cervical cancer screening in Romania.","volume":"183","author":"Andreassen","year":"2017)","journal-title":"Soc Sci Med"},{"key":"R3-20230902","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1016\/j.ejca.2009.07.017","article-title":"Description of the national situation of cervical cancer screening in the member states of the European Union.","volume":"45","author":"Anttila","year":"2009","journal-title":"Eur J Cancer"},{"key":"R5-20230902","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1177\/030089161009600406","article-title":"Cervical cancer assessment in Romania under EUROCHIP-2.","volume":"96","author":"Apostol","year":"2010)","journal-title":"Tumori"},{"key":"R7-20230902","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/cncy.21544","article-title":"Comparison of cervical cancer screening results among 256 648 women in multiple clinical practice.","volume":"123","author":"Blatt","year":"2015)","journal-title":"Cancer Cytopathol"},{"key":"R8-20230902","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.3892\/ol.2016.4903","article-title":"HPV strain distribution in patients with genital warts in a female population sample.","volume":"12","author":"Boda","year":"2016)","journal-title":"Oncol Lett"},{"key":"R9-20230902","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1002\/ijc.2910520514","article-title":"Risk factors for cervical cancer in Colombia and Spain.","volume":"52","author":"Bosch","year":"1992)","journal-title":"Int J Cancer"},{"key":"R10-20230902","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1086\/657321","article-title":"Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings.","volume":"202","author":"Bruni","year":"2010)","journal-title":"J Infect Dis"},{"key":"R11-20230902","doi-asserted-by":"crossref","first-page":"e4242","DOI":"10.1097\/MD.0000000000004242","article-title":"Participation in cancer screening among female migrants and non-migrants in Germany: a cross-sectional study on the role of demographic and socioeconomic factors.","volume":"95","author":"Brzoska","year":"2016)","journal-title":"Medicine (Baltimore)"},{"key":"R12-20230902","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13027-015-0009-x","article-title":"HPV prevalence and risk of pre-cancer and cancer in regular immigrants in Italy: results from HPV DNA test-based screening pilot programs.","volume":"10","author":"Campari","year":"2015)","journal-title":"Infect Agent Cancer"},{"key":"R13-20230902","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1097\/AOG.0b013e3181996ffa","article-title":"Five-year experience of human papillomavirus DNA and papanicolaou test cotesting.","volume":"113","author":"Castle","year":"2009)","journal-title":"Obstet Gynecol"},{"key":"R14-20230902","doi-asserted-by":"crossref","first-page":"20","DOI":"10.7326\/M17-1609","article-title":"Effect of several negative rounds of human papillomavirus and cytology co-testing on safety against cervical cancer: an observational cohort study.","volume":"168","author":"Castle","year":"2017)","journal-title":"Ann Intern Med"},{"key":"R15-20230902","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1093\/jnci\/djt051","article-title":"Genome-wide association study of susceptibility locifor cervical cancer.","volume":"105","author":"Chen","year":"2013)","journal-title":"J Natl Cancer Inst"},{"key":"R16-20230902","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1093\/annonc\/mdt538","article-title":"Cervical cancer screening: on the way to a shift from cytology to full molecular screening.","volume":"25","author":"Dijkstra","year":"2014)","journal-title":"Ann Oncol"},{"issue":"Suppl 5)","key":"R18-20230902","doi-asserted-by":"crossref","first-page":"F12","DOI":"10.1016\/j.vaccine.2012.07.055","article-title":"Global burden of human papillomavirus and related diseases.","volume":"30","author":"Forman","year":"2012)","journal-title":"Vaccine"},{"key":"R19-20230902","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1128\/JCM.01047-13","article-title":"Clinical impact of the analytical specificity of the hybrid capture 2 test: data from the New Technologies for Cervical Cancer (NTCC) Study.","volume":"51","author":"Gillio-Tos A","year":"2013)","journal-title":"J Clin Microbiol"},{"key":"R20-20230902","doi-asserted-by":"crossref","first-page":"h2372","DOI":"10.1136\/bmj.h2372","article-title":"HPV testing as a screen for cervical cancer.","volume":"350","author":"Goodman","year":"2015)","journal-title":"BMJ"},{"key":"R21-20230902","doi-asserted-by":"crossref","first-page":"e 13711","DOI":"10.1371\/journal.pone.0013711","article-title":"Effectiveness of VIA, Pap, and HPV DNA testing in a cervical cancer screening program in a peri-urban community in Andhra Pradesh, India.","volume":"5","author":"Gravitt","year":"2010)","journal-title":"PLoS One"},{"key":"R22-20230902","doi-asserted-by":"crossref","first-page":"3680","DOI":"10.1128\/JCM.02078-05","article-title":"Cross-sectional comparison of an automated hybrid capture 2 assay and the consensus GP5+\/6+ PCR methods in a population-based cervical screening program.","volume":"44","author":"Hesselink","year":"2006)","journal-title":"J Clin Microbiol"},{"key":"R23-20230902","first-page":"330","article-title":"Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance.","volume":"125","author":"Huh","year":"2015)","journal-title":"Gynecol Oncol"},{"key":"R24-20230902","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1186\/s12885-016-2961-2","article-title":"HPV prevalence in the Dutch cervical cancer screening population (DuSC study): HPV testing using automated HC2, Cobas and Aptima workflows.","volume":"16","author":"Huijsmans","year":"2016)","journal-title":"BMC Cancer"},{"key":"R25-20230902","doi-asserted-by":"crossref","first-page":"110","DOI":"10.5468\/OGS.2013.56.2.110","article-title":"Type-specific prevalence of high-risk human papillomavirus by cervical cytology and age: data from the health check-ups of 7014 Korean women.","volume":"56","author":"Kim","year":"2013)","journal-title":"Obstet Gynecol Sci"},{"key":"R26-20230902","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/cyt.12236","article-title":"HPV primary cervical screening: time for a change.","volume":"26","author":"Kitchner","year":"2015","journal-title":"Cytopathology"},{"key":"R27-20230902","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1038\/bjc.2013.647","article-title":"Type-and age-specific distribution of human papillomavirus in women attending cervical cancer screening in Finland.","volume":"109","author":"Leinonen","year":"2013)","journal-title":"Br J Cancer"},{"key":"R28-20230902","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1093\/eurpub\/ckx093","article-title":"Barriers to cervical cancer screening faced by immigrants: a registry-based study of 1.4 million women in Norway.","volume":"27","author":"Leinonen","year":"2017)","journal-title":"Eur J Publ Health"},{"key":"R29-20230902","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1038\/bjc.2015.248","article-title":"Understanding cervical screening non-attendance among ethnic minority women in England.","volume":"113","author":"Marlow","year":"2015","journal-title":"Br J Cancer"},{"key":"R30-20230902","first-page":"1823","article-title":"Distribution of HPV genotypes in patients from Cluj County, Romania.","volume":"15","author":"Matei","year":"2014)","journal-title":"J Environ Prot Ecol"},{"key":"R31-20230902","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1093\/oxfordjournals.aje.a112220","article-title":"Estimability and estimation in case-referent studies.","volume":"103","author":"Miettinen","year":"1976)","journal-title":"Am J Epidemiol"},{"key":"R33-20230902","doi-asserted-by":"crossref","first-page":"H59","DOI":"10.1016\/j.vaccine.2013.03.029","article-title":"Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Central and Eastern Europe.","volume":"315","author":"Poljak","year":"2013)","journal-title":"Vaccine"},{"key":"R34-20230902","doi-asserted-by":"crossref","first-page":"e59765","DOI":"10.1371\/journal.pone.0059765","article-title":"Prevalence of human papillomavirus in 5,072 consecutive cervical SurePath samples evaluated with the Roche Cobas HPV real-time PCR assay.","volume":"8","author":"Preisler","year":"2013)","journal-title":"PLoS One"},{"key":"R35-20230902","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1177\/1536867X0400400404","article-title":"Confidence intervals for the kappa statistic.","volume":"4","author":"Reichenheim","year":"2004)","journal-title":"Stata J"},{"key":"R36-20230902","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1002\/ijc.28666","article-title":"Smoking as a major risk factor for cervical cancer and pre-cancer: results from the EPIC cohort.","volume":"135","author":"Roura","year":"2014)","journal-title":"Int J Cancer"},{"key":"R37-20230902","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1128\/JCM.00896-09","article-title":"Optimal threshold for a positive hybrid capture 2 test for detection of human papillomavirus: data from the ARTISTIC trial.","volume":"48","author":"Sargent","year":"2010)","journal-title":"J Clin Microbiol"},{"key":"R39-20230902","doi-asserted-by":"crossref","first-page":"e79156","DOI":"10.1371\/journal.pone.0079156","article-title":"Human papillomavirus type-specific prevalence in the cervical cancer screening population of Czech women.","volume":"8","author":"Tachezy","year":"2013)","journal-title":"PLoS One"},{"key":"R40-20230902","doi-asserted-by":"crossref","first-page":"46.e1","DOI":"10.1016\/j.ajog.2011.07.024","article-title":"The ATHENA human papillomavirus study: design, methods, and baseline results.","volume":"206","author":"Wright","year":"2012)","journal-title":"Am J Obstet Gynecol"}],"container-title":["European Journal of Cancer Prevention"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CEJ.0000000000000522","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T01:05:48Z","timestamp":1693616748000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CEJ.0000000000000522"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/cej.0000000000000522","relation":{},"ISSN":["0959-8278"],"issn-type":[{"value":"0959-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]}}}